SIX-YEAR TERIPARATIDE (RHPTH 1-34) REPLACEMENT THERAPY IN A PATIENT WITH HYPOPARATHYROIDISM AND MALABSORPTION DUE TO AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1

被引：0
|
作者：
Grebennikova, T. [1 ]
Sozaeva, L. [1 ]
Orlova, E. [1 ]
Kareva, M. [1 ]
Sviridenko, N. [1 ]
Belaya, Z. [1 ]
机构：
[1] Natl Med Res Ctr Endocrinol, Moscow, Russia
来源：
OSTEOPOROSIS INTERNATIONAL | 2020年 / 31卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P910
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 50 条
  • [1] Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
    Ste-Marie, LG
    Schwartz, SL
    Hossain, A
    Desaiah, D
    Gaich, GA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) : 283 - 291
  • [2] Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I
    Högenauer, C
    Meyer, RL
    Netto, GJ
    Bell, D
    Little, KH
    Ferries, L
    Santa Ana, CA
    Porter, JL
    Fordtran, JS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (04): : 270 - 274
  • [3] An endocrine mechanism for severe malabsorption in a patient with autoimmune polyglandular syndrome type 1 (APS 1).
    Hogenauer, C
    Meyer, R
    Little, KH
    Ferries, L
    Porter, JL
    Santa Ana, CA
    Fordtran, JS
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1125 - A1125
  • [4] Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I.
    Creutzfeldt, W
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01): : 64 - 65
  • [5] Parathyroid hormone 1-34 (teriparatide) replacement therapy for hypoparathyroidism. A lesson from the impact on bone remodelling markers
    Al-bahrani, A.
    Dutton, J.
    Hine, T.
    Gittoes, N.
    Fraser, W. D.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : 377 - 377
  • [6] Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment
    Spanakis, E. K.
    Sellmeyer, D. E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (04) : 1411 - 1414
  • [7] Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism
    Tuli, Gerdi
    Buganza, Raffaele
    Tessaris, Daniele
    Einaudi, Silvia
    Matarazzo, Patrizia
    de Sanctis, Luisa
    [J]. ENDOCRINE, 2020, 67 (02) : 457 - 465
  • [8] The managing your osteoporosis (MYO) program for patients starting therapy with teriparatide injection [rhPTH (1-34)]
    Drews, T.
    Valentine, V.
    Wong, M.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (06): : 1085 - 1085
  • [9] Hypoparathyroidism as the single major component for decades of autoimmune polyglandular syndrome type 1
    Ferreira, Joana Lima
    de Carvalho, Francisco Simoes
    Marques, Ana Paula
    Principe, Rosa Maria
    [J]. ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2020,
  • [10] Challenges in Management of Primary Hypoparathyroidism Associated with Autoimmune Polyglandular Syndrome Type 1
    Wallace, I. R.
    McConnell, V.
    Bell, P. M.
    Lindsay, J. R.
    [J]. CASE REPORTS IN ENDOCRINOLOGY, 2011, 2011
12345